Initial target enrollment surpassed in fewer than seven months; trial expanded due to high demand First data presentation expected before year-end; sNDA submission by mid-2026 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). "We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial size due to overwhelming interest," said Ben Palleiko, CEO of KalVista. "The high

–Announced seventh regulatory application submission and secured orphan drug designation for sebetralstat in Japan for hereditary angioedema– – Presented new data that showed effectiveness of sebetralstat to address critical unmet needs in laryngeal attacks, adolescents with HAE and patients experiencing attacks despite long-term prophylaxis (LTP)– –Will host virtual investor day to discuss commercialization strategy ahead of June PDUFA– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update. "Sebetralstat is poised to be the first and only oral on-demand treatment for HAE, wi

Webcast scheduled for Tuesday, March 25 at 8:00 am ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company's investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here. In addition to presentations by KalVista's management team, leading external experts in HAE will discuss the current treatment guidelines and unmet needs for people living with HAE, and how sebetralstat could provide a new treatment option. A live question-and-

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on March 3, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with

–Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief– –Pooled data analysis showed adolescents treated with sebetralstat in median 4 minutes compared to over 3 hours in surveys – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. "The growing body of data from the KONFIDENT-S study consistently

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025, at 8:00 a.m. ET in Miami, FL Each presentation will be live webcast on the Company's website at www.kalvista.com. After the presentations, an audio archive will be available on KalVista's website for 30 days. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delive

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. The following poster presentations will take place on Friday, February 28, 2025, from 2:45–3:45 pm PT in the Convention Center, Ground Level, Hall A: Barriers to Timely On-demand Treatment of Hereditary Angioedema Attacks in Italian Patients (#180): Mauro Cancian, Paola Triggianese, Pietro Accardo, Francesco Arcoleo, Donatella Bignardi, Caterina Colangelo, Francesco Giardino, Antonio Gidaro, Mari

– Claims data show 40% of patients on long-term prophylaxis have gaps in prescription refills, leading to greater on-demand use and higher rate of LTP discontinuation- -Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours - –Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an all-oral regimen– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place i

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted fifty-two newly-hired employees inducement options to purchase an aggregate of 261,000 shares of KalVista common stock on February 3, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued ser

–Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan– – Submission advances Company's strategic plan to address unmet needs in HAE on global scale– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older, would be th

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $42.00 from $48.00 previously

Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $50.00 previously

SVB Leerink resumed coverage of KalVista Pharmaceuticals with a rating of Buy

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

HC Wainwright & Co. reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $30.00 previously

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company's Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. "We welcome Bill to our Board of Directors," said Ben Palleiko, CEO of KalVista. "His experience in commercial and me

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and th

– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that Benjamin L. Palleiko, the Company's current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned tr

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725517894/en/KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire) "As KalVista prepares for our evolution into a commercial organization, we continue to strategically add individuals with deep experience in hereditary angioedema (HAE) product launches and global commercialization," said Andrew Cro

– Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that the Board of Directors has appointed current member Brian J.G. Pereira, M.D., as Chairman, effective immediately. In conjunction, current Chairman Martin Edwards, M.D. has resigned from the Board in a planned transition concurrent with the Company's annual meeting. "We are pleased that Brian has agreed to take the Chairman role at this critical time," said Andrew Crockett, Chief Executive Officer of K

– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022. "We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise," said Andrew Crockett, Chief Executive Officer of KalVista. "We are me

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005196/en/KalVista CMO Paul Audhya (Photo: Business Wire) "As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage drug development and global commercialization," said Andrew Crockett, Chief Executive O